- Home
- ITRM
as 09-12-2025 4:00pm EST
Iterum Therapeutics PLC is a pharmaceutical company dedicated to maximizing the commercial potential of Orlynvah, an oral-branded penem available in the United States and potentially the first and only oral and intravenous (IV) branded penem available globally. Its product Orlynvah has the potential to be a treatment for complicated urinary tract infections caused by the designated microorganisms, without the presence of known toxicities of some other antibiotics. The company operates in a single business segment, which is the development and commercialization of treatments for drug-resistant bacterial infections.
| Founded: | 2015 | Country: | Ireland |
| Employees: | N/A | City: | DUBLIN 1 |
| Market Cap: | 40.0M | IPO Year: | 2018 |
| Target Price: | $7.00 | AVG Volume (30 days): | 749.8K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 2 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.80 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.61 - $3.02 | Next Earning Date: | 11-13-2025 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | 249.35% |
Stock Insider Trading Activity of Iterum Therapeutics plc (ITRM)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Dunne Michael W. | ITRM | N/A | Aug 8 '25 | Buy | $0.72 | 15,000 | $10,854.00 | 235,001 |
Latest Iterum Therapeutics plc News
ITRM Breaking Stock News: Dive into ITRM Ticker-Specific Updates for Smart Investing
GlobeNewswire
2 months ago
Iterum Names Christine Coyne as Chief Commercial Officer to Lead ORLYNVAH™ Launch and Commercial Growth
GlobeNewswire
3 months ago
Iterum Therapeutics Announces Publication of REASSURE Trial in NEJM Evidence
GlobeNewswire
3 months ago
Iterum Therapeutics Announces Partnership for Commercialization Services
GlobeNewswire
4 months ago
Iterum Therapeutics Announces Extension of Term of Promissory Note
GuruFocus.com
4 months ago
Iterum Therapeutics PLC (ITRM) Q1 2025 Earnings Call Highlights: Strategic Moves and Financial ...
Thomson Reuters StreetEvents
4 months ago
Q1 2025 Iterum Therapeutics PLC Earnings Call
GlobeNewswire
4 months ago
Iterum Therapeutics Reports First Quarter 2025 Financial Results
Simply Wall St.
4 months ago
Iterum Therapeutics plc (NASDAQ:ITRM): When Will It Breakeven?
Compare ITRM vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "ITRM Iterum Therapeutics plc - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.